RJA
CLRB icon

Raymond James & Associates’s Cellectar Biosciences CLRB Stock Holding History

Raymond James & Associates’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,201
Closed -$143K – 3983
2024
Q1 		$143K Buy
+1,201
New +$130K ﹤0.01% 3685

Other funds holding CLRB

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's CLRB Position: Q2 2024 in Review

Raymond James & Associates sold out of Cellectar Biosciences (CLRB) in Q2 2024, closing a stake of 1,201 shares — an estimated $143K sold.

Raymond James & Associates first reported a position in CLRB in Q1 2024 and held it in 1 quarter. The position peaked at $143K in Q1 2024. 37 funds tracked by Wall St. Rank hold CLRB as of Q2 2024.

  • Raymond James & Associates reported no remaining Cellectar Biosciences position as of Q2 2024 after selling out during the quarter.
  • Raymond James & Associates sold 1,201 Cellectar Biosciences shares in Q2 2024, an estimated $143K.
  • Raymond James & Associates first reported a position in Cellectar Biosciences in Q1 2024 and held it in 1 quarter.
  • Raymond James & Associates's Cellectar Biosciences position peaked at $143K in Q1 2024.
  • 37 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2024.

Based on Raymond James & Associates's 13F filing for Q2 2024, filed 19 Jul 2024.